Virax Biolabs Group Limited (VRAX)

Virax Biolabs Group will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Data will show when the stock starts trading.
Market Capn/a
Revenue (ttm)109,820
Net Income (ttm)-859,943
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Ex-Dividend Daten/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Price Targetn/a
Earnings Daten/a

About VRAX

Virax Biolabs Group is a holding company incorporated with no material operations of its own. We conduct our substantial operations in the United Kingdom and Hong Kong with operating subsidiaries in Singapore, China and British Virgin Islands and have been operating since 2013. We are a global innovative biotechnology group that primarily engages in sales, distribution and marketing of diagnostics test kits and med-tech and Personal Protective Equipment products for the prevention, detection, diagnosis and risk management of viral diseases with...

IndustryHealth Care
CEOJames Foster
Stock ExchangeNASDAQ
Ticker SymbolVRAX
Full Company Profile

Financial Performance

In 2020, VRAX's revenue was $123,820, an increase of 23.97% compared to the previous year's $99,876. Losses were -$672,915, -9.00% less than in 2019.

Financial Statements


Virax Biolabs Group IPO Registration Document (F-1)

Virax Biolabs Group has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC